secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001193125-25-328747
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5M total
--------------------------------------------------------------------------

- Acquires equity of StrataDx for $12.5M cash; asset purchase from Bako entities for $43.0M cash.
- Deal expected to close in first half 2026; subject to regulatory approvals and customary conditions.
- Adds anatomic pathology, proprietary PCR tests, nationwide sales team, and CLIA/CAP labs in GA and MA.
- Fulgent plans to leverage AI and digital pathology (Eziopath) to improve efficiency at acquired labs.
- Acquisition funded from cash on hand; Fulgent notes organic double-digit growth in lab services business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000119312525328747/0001193125-25-328747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000119312525328747/flgt-20251220.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-328747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer